Liver stem cells—prospects for clinical use David Tosh, Alastair Strain  Journal of Hepatology  Volume 42, Issue 1, Pages S75-S84 (April 2005) DOI: 10.1016/j.jhep.2004.12.009 Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Confocal immunofluorescence staining of human liver sections with the antibody GCTM5. Sections were co-stained with the biliary marker CK19 (Green), GCTM% (Red) and co-localisation showing in yellow in normal (A), Primary Biliary Cirrhosis (B) and Extra-hepatic Biliary Atresia (C) tissue. In each case the GCTM5 antibody recognises a sub-set of cells stained positive for CK19. In addition small number of discrete GCTM5 positive only cells are observed, even in normal tissue which may represent cells of the Canals of Hering. Journal of Hepatology 2005 42, S75-S84DOI: (10.1016/j.jhep.2004.12.009) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Conversion of pancreatic cells to hepatocytes. Control pancreatic cells express the exocrine digestive enzyme, amylase (A). Following dexamethasone treatment, some cells still express amylase (red) but a few flatten and start to express a liver phenotype based the gluconeogenic enzyme, glucose-6-phosphatase expression (green) (B). Journal of Hepatology 2005 42, S75-S84DOI: (10.1016/j.jhep.2004.12.009) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions